INDICATIONS AS APPROVED BY THE ISRAELI MOH:
Sandostatin LAR (Octreotide acetate)
Treatment of acromegaly in: Patients already adequately controlled on standard doses of sandostatin s.c.
Patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period
before radiotherapy becomes fully effective (Sandostatin LAR is injected intragluteally)
Endocrine Gastro-Entero-Pancreatic (GEP) tumors, carcinoid tumors.
Sandostatin (Octreotide) Prevention of complications following pancreatic surgery.
Symptomatic control and reduction of growth hormone (GH) and IGF-1 plasma levels in patients with
acromegaly who are inadequately controlled by surgery or radiotherapy. Sandostatin treatment is also indicated
for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy
becomes fully effective.
Relief of symptoms associated with functional gastro-entero-pancreatic (GEP) endocrine tumors:
● Carcinoid tumors with features of the carcinoid syndrome.
● Gastrinomas/Zollinger-Ellison syndrome, usually in conjunction with proton pump inhibitors,
or H2-antagonist therapy.
● Insulinomas, for pre-operative control of hypoglycemia and for maintenance therapy.
Sandostatin is not an anti-tumors therapy and is not curative in these patients.
Emergency management of bleeding gastro-esophageal varices secondary to cirrhosis in combination with
specific therapy such as endoscopic sclerotherapy.
Signifor LAR (Pasirotide LAR) is indicated for the treatment of adult patients with acromegaly for
whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with
another somatostatin analogue.
Signifor (Pasireotide diaspertate) Treatment of adult patients with Cushing’s disease for whom
surgery is not an option or for whom surgery has failed.